Corium International, Inc. Announces Appointment of Phyllis Gardner, M.D. and Daniel G. Welch to Board

MENLO PARK, Calif., Nov. 27 /PRNewswire/ -- Corium International, Inc., a privately-held transdermal drug delivery company, today announced the appointment of Phyllis Gardner, M.D. and Daniel G. Welch to the Board of Directors. Dr. Gardner, an adjunct partner at Essex Woodlands Health Ventures, is a Professor of Medicine at Stanford University and widely published in the fields of cell biology and pharmacology. In addition to her academic work, Dr. Gardner has been active in the biotechnology and pharmaceutical industries. In 1996, she took a leave of absence from Stanford and joined ALZA Corporation as a Principal Scientist, Vice President of Research, and Head of the ALZA Technology Institute. Dr. Gardner is the co-founder of Genomics Collaborative, Inc. (now a division of Bioserve), SKOLAR MD (acquired by Wolters Klure) and APEX DX, LLC. She currently serves on the boards of Ventaira Pharmaceuticals, UMD, Inc., and Revance, Inc., and she is on the Scientific Advisory Board of Aradigm Corp. Dr. Gardner received her M.D. from Harvard Medical School, and received postgraduate training at Massachusetts General Hospital, Stanford School of Medicine, Columbia University and University College London.

Daniel G. Welch has served as Chief Executive Officer and President of InterMune since September 2003. Prior to InterMune, Mr. Welch was Chairman and CEO of Triangle Pharmaceuticals, a biopharmaceutical company, which was acquired by Gilead. From 2000 to 2002, he was President of Biopharmaceuticals at Elan Corporation where he was responsible for U.S. commercial operations, the international subsidiaries, the R&D function and the diagnostics businesses. Mr. Welch served in several senior management roles at Sanofi-Aventis during the years 1987 to 2000, including Vice President of Worldwide Marketing and COO of the U.S. business. Prior to joining Sanofi-Aventis, Mr. Welch was with American Critical Care, a division of American Hospital Supply. Mr. Welch is a member of the Board of Directors of Seattle Genetics, Inc. and BayBio, the bay-area biotech industry association. He holds an M.B.A. from the University of North Carolina and a B.B.A. from the University of Miami.

Dr. Gardner and Mr. Welch join current Corium board members John Kozarich, Chairman and President, ActivX Biosciences, Inc., Ron Eastman, Chairman of the Board and Partner at Essex Woodlands Health Ventures, Robert Thomas, CEO of Corium and former FoxHollow Technologies CEO, Gary Cleary, co-founder of Corium and CTO, and Ravi Srinivasan, co-founder of Stratagent Life Sciences and VP of Engineering at Corium. The Company recently completed a $25.1 million Series C financing led by Essex Woodlands Health Ventures. Corium is using the proceeds to continue the development and commercialization of a pipeline of advanced transdermal products employing its proprietary MicroCor(TM) microneedle technology, Corplex(TM) polymer adhesive technology, and MicroJet liquid drug delivery technology.

Corium is headquartered in Menlo Park, CA, with manufacturing facilities in Grand Rapids, MI.

About Corium International, Inc.

Corium International, Inc. is a privately-owned company engaged in the research, development and manufacture of advanced transdermal drug delivery technologies and products. Using its proprietary delivery technologies and its development and manufacturing expertise, Corium has developed a number of active and passive transdermal products with enhanced therapeutic or safety profiles. This self-funded product pipeline spans several therapeutic areas and is in various stages of development. Corium also has several partner-funded products with small, medium and large pharmaceutical companies in various stages of development, ranging from manufacturing to research and development. Please visit http://www.coriumgroup.com

About Essex Woodlands Health Ventures

With $1.6 billion under management, Essex Woodlands is one of the nation’s largest and oldest venture capital firms pursuing investments in pharmaceuticals, biotechnology, medical devices, health services, managed care and health information. Since its founding in 1985, Essex Woodlands has maintained its singular commitment to the healthcare industry and has been involved in the founding, investing, and/or management of over 100 healthcare companies ranging across all sectors, stages and geography, and brings over 240 years of collective healthcare experience. The team is comprised of 23 professionals with principal offices in Palo Alto, California, Houston, Texas, New York City and London. For more information, please see http://www.ewhv.com.

christina@coriumtech.com

CONTACT: Christina Dickerson, Director, Corporate Development of Corium
International, Inc., +1-650-298-8257, christina@coriumtech.com

Web site: http://www.coriumtech.com/
http://www.ewhv.com/

MORE ON THIS TOPIC